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1. ABSTRACT
Cyclin dependent kinase 9 (Cdk9) is a member of the cyclin dependent kinase family. This 
protein is a seorine-threonine kinase, involved in many cellular processes. The regulatory  units of 
Cdk9 are the T family Cyclins (T1, T2) and Cyclin K1. Cyclin T2 has two forms termed CycT2a 
and CycT2b that arise by an alternative splicing of the primary  transcript. Human Cyclins T2a 
and T2b share the first 642 amino acids but have different carboxyl termini. Previous studies 
underscored a crucial role for Cdk9 in association of Cyclin T2 during skeletal myogenesis. 
Upon induction of muscle differentiation, MyoD recruits Cdk9/CycT2 on muscle-specific gene 
promoter sequences. This complex is able to phosphorylate the C-terminal domain of RNA 
polymerase II, enhancing Myod function and promoting myogenic differentiation. 
Rhabdomyosarcoma (RMS), one of the most common childhood solid tumor, arises from muscle 
precursor cells and fails to complete both the differentiation program both the irreversibly cell 
cycle exit, resulting in uncontrolled proliferation and incomplete myogenesis. In RMS, Cdk9 
fails to phosphorylate MyoD and the ability of MyoD to arrest cell proliferation and to activate 
the myogenic program is repressed. The result of this study confirmed the involvement of Cdk9/
CyclinT2 complexes during the myogenesis. Both isoforms of Cyclin T2 are able to activate the 
myogenic program at different stages of differentiation but CycT2b have a predominant role in 
particular during the latest stages. Moreover we demonstred that EZH2 is probably responsible to 
inhibition of Cdk9 in RMS cells and her overexpression contribuite to inhibition of muscle 
differentiation program.
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2. INTRODUCTION
2.1 Differentiation of skeletal muscle
The identity, proliferation and terminal differentiation of skeletal muscle cells is controlled by 
combinatorial activities of several transcription factors (Sartorelli and Caretti, 2005).
In particular, an important “modulatory” role in the development of skeletal muscle tissue is 
performed by a family  of transcription factors, which have in common a basic helix-loop-helix 
DNA binding domain, called myogenic bHLH family. This transcription factors family includes 
MyoD (reviewed by Weintraub et al., 1991), myogenin (Braun et al., 1989a; Edmondson and 
Olson, 1989; Wright et al., 1989), Myf-5 (Braun et al., 1989b), and MRF4, or Myf-6/herculin, 
factors. (Rhodes and Konieczny, 1989; Braun et al., 1990; Miner and Wold, 1990; Rudnicki et 
al., 1993).
During the skeletal muscle differentiation process, this family of muscle-restricted bHLH 
proteins activate the differentiation program by binding to sequence-specific DNA elements, E 
box sites (CANNTG), located in enhancer and promoter sequences of muscle specific genes 
(Lassar et al., 1989), and by  inducing the transcription of regulatory and structural muscle 
specific genes (Lassar and Munsterberg, 1994; Molkentin and Olson, 1996; Yun and Wold, 1996; 
Arnold and Winter, 1998). Notably, efficient MyoD DNA-protein-binding is achieved by 
heterodimerization with other non-myogenic bHLH proteins, which include the products of the 
E2A gene (E12, E47) and HEB, also referred as E proteins (Murre et al., 1989; Lassar et al., 
1991; Puri and Sartorelli, 2000).
The cardinal role of MyoD in skeletal myogenesis is evinced by the amount of its target genes. In 
fact, MyoD regulates more than 300 genes that could be grouped into at least eight categories: 
1. adhesion/matrix
2. cell cycle/DNA replication
3. grow factors/ligand
4.  metabolism
5. nuclear regulatory factors
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(Bergstrom et al., 2002; Giacinti et al., 2006). 
Each MyoD monomer forms two α helics interrupted by a short stretch of aminoacids modeled 
as a loop. The first α helix (H1) includes the basic and the helix1 domains; the second helix (H2) 
starts immediately after the loop and ends at aminoacid 166. The basic domain fits in the major 
groove of the DNA, establishes most of the DNA-protein interactions and is involved in the 
activation of transcription (Davis and Weintraub, 1992; Puri and Sartorelli, 2000). Instead, the 




Figure 1: A) Domains organization of Myod. B) bHLH domain C) Schematic representation of 
MyoD-DNA binding.
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Interestingly, the bHLH proteins MyoD, its interacting partners E12, E47 and c-myc recognize 
similar, yet  distinct, E-boxes. In fact, in vitro experiments have established that MyoD prefers 
the CAGCTC sequence, whereas E47 selects the CACCTG, and c-Myc the CACGTG motif, 
respectively (Blackwell et al., 1990; Blackwell and Weintraub, 1990; Blackwell et al., 1993; Puri 
and Sartorelli, 2000).
Full activation of muscle gene expression by  MRFs is also dependent by their association with 
members of the MEF2 transcription factors family. In fact, it has been reported that MEF2 
factors cannot activate muscle genes on their own, but they potentiate the activity of MRFs. 
(Sartorelli and Caretti 2005; Lluìs et al., 2006).
Other than bHLH non-myogenic factors, MyoD can recruit transcriptional co-activators p300 
and PCAF, two histone acetyltransferases (HATs) that promote muscle gene transcription by 
inducing acetylation of both chromatin and sequence-specific transcription factors, as for MyoD 
(Eckner et al., 1994; Eckner et al., 1996; Yuan et al., 1996; Sartorelli et al., 1997; Puri et al., 
1997a,c; Puri et al., 1997c; Struhl, 1998; Giordano and Avantaggiati, 1999; Sartorelli et al., 
1999; Puri and Sartorelli, 2000; Iezzi et al., 2002). Significantly, p300/CBP directly interacts 
with MyoD and conveys transcriptional competency by  contacting proteins present in the TFIID 
complex and the basal transcription machinery (Eckner et al., 1996; Yuan et al., 1996; Sartorelli 
et al., 1997; Puri et al., 1997c; Giacinti et al., 2006).
2.2 Interplay between proliferation, differentiation and rhabdomyosarcoma
A clear and effective statement asserts that cell proliferation and differentiation are mutually 
exclusive events. In muscle cells, as in other cell types, the decision to divide or differentiate is 
determined by a balance of opposing cellular signals (Olson, 1992). 
Several HLH proteins have been characterized as inhibitors of myogenesis which exert  their 
activity by distinct mechanisms:
1. Inhibition of myogenic bHLH proteins by direct protein-protein interaction: Id (Benezra et al., 
1990), Twist (Hamamori et al., 1997), I-mfa (Chen et al., 1996), Cdk4-CyclinD1 (Zhang et al., 
1999a)
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2. Displacement of E12/47: Id- E12/47 complex (Jen et al., 1992)
3. Competition for DNA binding sites: MyoR (Lu et al., 1999), Mist (Lemercier et al., 1998) and 
ZEB (Postigo and Dean, 1997; Postigo et al., 1999)
4. Cytoplasmic retention of myogenic bHLH proteins: I-mfa (Chen et al., 1996)
Numerous proteins either facilitate or are required in order to enhance myogenic bHLH 
transcriptional activity. Some of these are transcriptional activators themselves, whereas others 
do not directly interact with sequence-specific DNA targets (coactivators).
For instance, as alredy  explained, MyoD forms a multiprotein complex with its heterodimeric 
partners, E12 or E47, and with acetyltransferases p300 and PCAF, whose histone acetylation 
alters nucleosomal conformation and increase accessibility  of transcription factors to DNA. 
Furthermore, PCAF-dependent MyoD acetylation stabilizes MyoD binding to DNA, presumably 
by inducing conformational changes in MyoD protein structure. Moreover, additional 
acetylations of the basal transcription machinery  are also involved in the activation of 
transcription (Puri and Sartorelli, 2000).
It is essential to stress that other proteins influence the myogenic program through several 
mechanisms. For instance, thyroid hormone (TH) and retinoic acid receptors (RAR and RXR) 
are functionally related to the activation of muscle-specific promoters (Carnac et al., 1992; 
Albagli-Curiel et al., 1993; Downes et al., 1993; Halevy and Lerman, 1993; Downes et al., 1994; 
Alric et al., 1998). Moreover, pRb is able to significantly upregulate MyoD activity  and is 
involved in the hexpression of late muscle differentiation markers, MHC and MCK (Gu et al., 
1993). 
Another crucial mechanism in the activation of myogenic program is established by  the multi-
protein chromatin-remodeling complex SWI/SNF, recruited on myogenic loci by a p38-
dependent mechanism. In fact, upon MKK6-dependent enzymatic activation, p38 localizes on 
the chromatin of muscle-gene regulatory elements promoting the recruitment of SWI/ SNF 
(Simone et al., 2004b). Thus, cofactor binding sites might help to expose a crucial E box or 
substitute for an E box facilitating the formation of stable and functional MyoD 
transcriptioncomplexes (Lluìs et al., 2006).
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Significantly, Rhabdomyosarcoma (RMS), one of the most common childhood solid tumor, 
arises from muscle precursor cells and fails to complete both the differentiation program and the 
irreversibly cell cycle exit, resulting in uncontrolled proliferation and incomplete myogenesis
(Merlino and Helman, 1999). Surprisingly, RMS cells express MyoD and myogenin to varying 
degrees, but they show only limited expression of genes associated with terminal differentiation 
(Hiti et al., 1989; Dias et al., 1991). Interestingly, the ability of MyoD to arrest  cell proliferation 
and to activate the myogenic program is repressed in RMS, hypothesizing a MyoD activity-
dependent inhibition of myogenesis (Tapscott et al., 1993; Otten et al., 1997).
2.3 Cdk9, Cyclin T and role in muscle differentiation.
Cyclin-dependent kinase 9 (cdk9), previously named PITALRE (Grana et al., 1994), is a cdk2-
related serine/threonine kinase, widely expressed in human and murine tissues with high protein 
levels in terminally differentiated cells (De Luca et al., 1997a; Bagella et al., 1998, 2000; 
Simone et al., 2002).
Cdk9 regulation and activity strictly differs from other CDKs. Cdk9 activity is not cell cycle-
dependent and it does not appear to be required in cell cycle progression (MacLachlan et al., 
1995; De Falco and Giordano, 1998). In addition, unlike the other cdks, Cdk9 fails to 
phosphorylate histone H1. In fact, it  is involved in the promotion of transcription elongation via 
phosphorylation of the carboxyl-terminal domain (CTD) of RNA polymerase II, converting the 
inactive unphosphorylated, pre-initiation complex into the phosphorylated and active form 
(Grana et al., 1994; Dahmus, 1996; Marshall et al., 1996; Zhu et al., 1997; Wei et al., 1998 
Simone et al., 2002; Soutoglou and Talianidis, 2002). The essential residues in transcription 
elongation are serine 2 and 5 (Zhou et al., 2001; Sano et al., 2002; Soutoglou and Talianidis, 
2002). 
CDK9 activity is regulated by cyclins T (T1, T2) and cyclin K (Fu et al., 1999).
Cyclin T1 and T2 share a highly conserved amino terminal motif (cyclin box region, 81% 
identity  in human T-cyclins), a putative coiled-coil motif, a His-rich motif ( responsible of the 
protein-protein interactions with the CTD of RNA polymerase II) and a carboxy- terminal PEST 
sequence (less conserved than cyclin box region, 46% identity in human T-cyclins) (Peng et al., 
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1998b; De Luca et al., 2003). The ‘‘cyclin homology box,’’ formed by 290 amino acids, is the 
most conserved region among different members of the cyclin-family and serves to bind CDK9.
Cyclin T2 has two isoforms, T2a and T2b, that likely arise by an alternative splicing of the 
primary transcript, which share the first 642 amino acids but have different carboxyl termini (De 
Luca et al., 2003) (Figure 2). Interestingly, CycT2 bears a leucine-rich stretch next to its cyclin 
box capable to bind to CTD of RNA polymerase II, thus providing an extra domain capable of 
targeting RNAPII (Peng et al., 1998; Kurosu et al., 2004).
Figure 2: Schematic representation of mRNA and protein structure of the two isoforms of cyclin 
T2.
In muscle differentiation, Cdk9 is one of the co-activators of MyoD necessary for the completion 
of the myogenic program (Simone and Giordano, 2001, 2007; Simone et al., 2002). Indeed, it 
has been demonstrated that  Cdk9 directly  interacts with MyoD in vitro (Simone et al., 2002). 
Moreover, recently  it has been shown that Cdk9, in muscle cells, takes part of a multimeric 
complex containing MyoD, cyclin T2, p300, PCAF and Brg1 (Giacinti et al., 2006). This 
complex binds to muscle-specific gene promoter regions and promote gene expression by 
Irene Marchesi, A novel role of Cyclin T2 complexes in skeletal muscle and Rhabdomyosarcoma 
cells, Scuola di Dottorato in Scienze Biomolecolari e Biotecnologiche - indirizzo Biochimica, 
Biochimica Clinica e Biologia Molecolare, Universita’ degli Studi di Sassari
inducing chromatin remodeling, through acetylation of specific lysine residues of histones H3 
and H4 and phosphorylation of RNA polymerase II CTD through Cdk9 (Simone et al., 2004; 
Giacinti et al., 2006; Simone and Giordano, 2007; Giacinti et al., 2008) (Figure 3). 
Figure 3: Schematic representation of the transcriptional complexes regulating gene 
expression in differentiation muscle cells.
Significantly, cyclin T1 was not detected on the same regions, suggesting cyclin T2-depedent 
Cdk9 activation (Giacinti et al., 2006).
Surprisingly, Rhabdomyosarcoma cells showed upregulation of both Cdk9 and Cyclin T2 and a 
strongest Cdk9-cyclinT2 interaction when compared to myoblasts, although Cdk9 fails to 
phosphorylate MyoD. It is important to stress that no mutations were detected in the coding 
sequences of Cdk9 and Cyclin T2 genes and no significant values muscle-specific gene 
expression was detected in presence of overexpressed MyoD in RD cells (Simone and Giordano 
2007).
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2.4 EZH2 and role in the regulation of muscle differentiation
Polycomb repressive complex 2 (PRC2) is a histone methyltransferase which is responsible of 
the tri-methylation of lysine-27 of histone H3 (H3-K27). (Cao et al., 2002; Czermin et al.,  2002; 
Kuzmichev et al., 2002; Muller et al., 2002).
PRC2 was initially purified and characterized from human cells and Drosophila embryos (Muller 
et al., 2002; Kuzmichev, et al., 2002; R. Cao et al., 2002; Czermin, et al., 2002); it contains a 
conserved catalytic subunit, termed EZH2 in human, that include the signature SET domain, 
which provides the methyltransferase active site (Rea et al., 2000). The SET domains have an 
unusual “thread-the-needle” structure, called pseudoknot (Cheng and Zhang, 2007; Dillon et al., 
2005 for reviews), formed by juxtaposition of two conserved peptide motifs with one peptide 
inserted through the loop  created by  the other. These structures show that the substrate lysine and 
methyl donor cofactor bind opposite sides of the SET domain with their binding pockets 
connected by an interior channel that aligns the reactive groups for methyl transfer. To attain 
robust histone methyltransferase activity, EZH2 must be complexed with at least two of its non 
catalytic partners, EED/ESC and SUZ12 (Cao and Zhang 2004; Pasini et al., 2004; Ketel et al., 
2005; Nekrasov et al., 2005; Montgomery et al., 2005). Both the C-terminal SET domain and the 
adjacent cysteine-rich (CXC) domain are required for histone methyltransferase activity  (Muller 
et al., 2002; Kuzmichev, et al., 2002; R. Cao et al., 2002; Cao and Zhang 2004). Instead, N-
terminal domains provide binding sites for assembly with the required partner subunits (Figure 
4).
Figure 4: Composition of PRC2 and domain organization of EZH2. (A) The four core 
subunits of human PRC2 are EZH2, EED, SUZ12 and RbAp48 (B) Five functional domains 
in EZH2.
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PRC2 enzyme function can also be influenced by another associated component, called PHF1 
(PCL in flies). Although PHF1 is not a core subunit of PRC2, its association with the complex 
can stimulate PRC2 enzyme activity and/or influence its recruitment to target genes in vivo 
(Nekrasov et al., 2007; Savla et al., 2008; Sarma et al., 2008; Cao et al., 2008).
Polycomb (PcG)-mediated modifications of histones is an essential mechanism that ensures the 
establishment and maintenance of gene expression pattern during mammalian development. 
(Sparmann and van Lohuizen 2006). Gene expression silencing by PcG proteins, characterized 
by the trimethylation of lysine 27 on histone 3 (H3K27me3) (Czermin et al., 2002; Muller et al., 
2002), is required at specific stages of development for the timely  expression of genes involved 
in stem cell fate and lineage commitment upon differentiation (Boyer et al., 2006; Lee et al., 
2006; Bracken et al., 2006; Pietersen and van Lohuizen, 2008) and for mammalian X-
inactivation and imprinting (Plath et al., 2003; Umlauf et al., 2004).
Polycomb silencing and DNA methylation have often been considered biochemically 
independent gene silencing systems. However, recent studies show that EZH2 and DNA 
methyltransferases (DNMTs) are physically and functionally linked and that EZH2 acts upstream 
of DNMTs to methylate and silence target chromatin (Virė et al., 2006). The mechanism is not 
yet clear, but an hypothesis is that target genes are initially silenced through histone H3-K27 
methylation by PRC2. PRC2 recruits DNA methyltransferases (DNMTs) which methylate CpG 
DNA of target genes, leading to a more permanently or deeply silenced chromatin state (Ohm et 
al., 2007; Schlesinger et al., 2007; Widschwendter et al., 2007). 
Moreover, in human cells, PRC2 can physically associate with HDAC1 and HDAC2. HDACs 
are not core subunits of PRC2 but transient interactions likely still provide functional synergy 
between these silencing enzymes in vivo. The precise mechanism of this synergy at target gene 
chromatin are not  yet clear. HDACs may deacetylate H3-K27 to make the ε-amino group 
available for methylation by PRC2. Alternatively, HDACs may deacetylate other histone lysines, 
such as H3-K9, H3-K14 or H4-K8, in order to adjust the local histone code for silencing (van 
Der Vlag and Otte, 1999; Muller et al., 2002; Kuzmichev et al., 2002; Cao et al., 2002; Czermin 
et al., 2002; Varambally et al., 2002; Cao and Zhang, 2004) (Figure 5).
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Figure 5: Model for collaboration of epigenetic silencing enzymes. Target  genes are initially 
silenced through histone H3-K27 methylation by PRC2. If the lysines are acetylated, may  first 
require deacetylation by  a histone deacetylase (HDAC). PRC2 may also recruit DNA 
methyltransferases (DNMTs)  which methylate CpG DNA of target genes, leading to a more 
permanently or deeply silenced chromatin state 
Polycomb-mediated gene silencing and DNA methylation underlie many epigenetic processes 
important in normal development as well as in cancer. 
Typically, EZH2 is down-regulated in adult differentiated tissues (Varambally et al., 2002; 
Bracken et al., 2003; Kleer et al., 2003). Moreover, in contrast to widespread EZH2 roles in 
early mouse development (O’Carroll et al., 2001; Erhardt et al., 2003), post-embryonic EZH2 
expression is limited (Hobert et al., 1996; Laible et al., 1997). Furthermore, even when detected 
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in adult tissues, EZH2 is concentrated in undifferentiated progenitor cell populations, such as 
hematopoietic cells of the pro-B lymphocyte lineage (Su et al., 2003). 
Interestingly, EZH2 is overexpressed in a variety  of different tumors. EZH2 levels are 
abnormally  elevated in cancer tissues versus corresponding normal tissues, with highest 
expression correlating with advanced stages of disease and poor prognosis (for review Simon 
and Lange 2008).
Significantly, numerous MyoD-target sequences in muscle-restricted gene promoter regions, 
silent in embryonic staminal cells, are occupied by PcG proteins marked by H3K27me3 (Lee et 
al., 2006). Moreover, in skeletal muscle cells (SMC), PcG proteins and H3K27me3 are no longer 
present at MyoD target-sequences, allowing for their transcriptional activation. Importantly, 
although MyoD is expressed in undifferentiated SMC, PcG proteins continue to bind certain 
MyoD target genes, which continue to be marked by H3K27me3 and silenced. After additional 
molecular signals that promote the complete myogenic program, initiate PcG binding and 
H3K27me3 are lost at MyoD target loci, resulting in appropriate muscle gene expression and 
SMC differentiation (Caretti et al., 2004; Juan et al., 2009) (Figure 6).
Furthermore, recent  studies showed that levels of Ezh2 transcript and protein in RMS compared 
to normal myoblasts are consistently higher (Ciarapica et al., 2009).  
These data suggest that EZH2 plays a key  role in skeletal-muscle differentiation, specifically in 
the maintenance of the undifferentiated state of muscle cell precursors. We hyphotesize that 
EZH2 overexpression may participate in Rhabdomyosarcoma formation and progression.
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Figure 6: Two-step activation model of muscle gene expression. Regulatory regions of certain 
muscle-specific genes are occupied by a protein complex containing the DNA-binding protein 
YY1, the methyltransferase Ezh2, and the deacetylase HDAC1. Deacetylation of lysine residues 
by HDAC1 and trimethylation of H3-K27 by Ezh2 actively prevent transcription (repressed 
state). At the triggering of transcriptional activation, YY1 is displaced from the chromatin, Ezh2 
and HDAC1 are replaced by SRF. H3-K27 becomes hypomethylated, and MyoD and HATs are 
recruited to the regulatory regions and allowing initiation of transcription (activated state).
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3. AIM OF THE PROJECT
Skeletal muscle differentiation is influenced by multiple pathways which regulate the activity of 
myogenic regulatory factors (MRFs) and the MEF2 family members, in positive or negative 
ways. 
Elucidating the mechanisms governing muscle-specific transcription will provide important 
insight to better understand the embryonic development of muscle at the molecular level and will 
have important implications in setting out new therapeutic strategy.
Rhabdomyosarcoma is a highly  malignant pediatric tumor that derive from mesenchymal cells 
already committed to become skeletal muscle cells. In this tumor, the activity of MRFs are 
compromised. Furthermore, recent studies showed that levels of EZH2, a protein involved in the 
regulation of muscle differentiation process, in rhabdomyosarcoma are consistently  higher 
compared to normal myoblasts.
The purpose of this study is the characterization of the two murine Cyclin T2 isoforms, CycT2a 
and CycT2b and the evaluation of their role in muscle differentiation program. Moreover the 
project focus on the modulation by PRC2 of specific skeletal muscle differentiation-related gene 
promoters and its involvement in rhabdomyosarcoma formation. In particular the study focus on 
the possible interaction between Cdk9/Cyclin T2 complexes and EZH2. 
This study will help to clarify the function of these proteins and the molecular regulation during 
the myogenic program tumor formation.
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4. MATERIALS AND METHODS
4.1 Cloning and Sequencing 
Rapid amplication of cDNA ends (RACE) was employed to generate complete cDNA sequence 
encoding the Cyclin T2 isoforms. Mouse skeletal muscle Marathon-ready cDNAs (Clontech) 
were used as templates in RACE polymerase chain reaction (PCR) to obtain the 5‘and 3’-end 
cDNA fragment according with the manufacture’s protocol
The PCR for 5’-end was carried out using Adaptor primer 1, included in the kit, as sense primer 
and CycT2rev1 (GCTTGCAAATGGTCCAATTGGG) as antisense primer. 
The PCR fo r 3 ’ - ends was ca r r i ed ou t u s ing CycT2afo r and CycT2bfo r 
(CCACGGTGCTCAGGAGTCCT; CAGCGGATGGAATGCCTCCC respectively) as sense 
primers and Adaptor primer 1 as antisense primer. 
PCR products were cloned into pGEM-T Easy Vector System II (Promega) and the sequenced 
using T7 and SP6 primers. The sequences are analyzed on the 3730 DNA Analyzer from Applied 
Biosystems.  





The plasmids Myogenin-luciferase Myh-luciferase promoter were constructed by PCR. The 
genomic DNA was extract  by DNeasy blood and tissue kit  (Qiagen) following the manufacture’s 
protocol. The PCR were performed with specific primers: 
Myogenin promoter for CAAACGCTAGCCAGCTCTCACGGCTGCTATGA
Myogenin promoter rev GGGAGATCTGGTAGAAATAGGGGGATGTCTC
Myh promoter for  CTCCCGGGCTGTATTTCCTCATCTGTGAGGA
Myh4 promoter rev: CTACAAGCTTAGACCAGTTGCTCCTATGCCC
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The amplifed products were cloned in the NheI-BglII site and XmaCI-HindIII of the pGL3 basic 
vector (Promega) for Myogenin promoter and Myh promoter respectively. 
The plasmids pcDNA3-CycT2a and pcDNA3-CycT2b were constructed by PCR using pGEM-T 




The amplifed products were cloned in the BamHI site of the pcDNA3 vector (Invitrogen)
The correct sequences of all these constructs were confirmed by sequencing using the 3730 DNA 
Analyzer from Applied Biosystems. The constructs pcDNA3-cdk9wt expressing full-length and 
Gst-cdk9 have been previously described (De Falco et al., 2000). The constructs expressing, 
MyoD and EZH2 have been described previously. (Simone et al., 2002; Tonini et al., 2004 
respectively).
4.3 Lentivirus production and infection 
293T packaging cell were seed at 1.5x105 cells/ml (6 ml per plate) in low-antibiotic growth 
media (DMEM + 10% FBS) in 6 cm tissue culture plates.
After 24 hours, the packaging cells were transfected with 3 lentivirus plasmids. 1µg  of Hairpin-
pLKO.1 vector (shRNA-EZH2 from Sigma), 0.9µg of packaging plasmid psPAX2, 0.1µg of 
envelope plasmid pMD2G were diluted in OPTI-MEM to total volume of 250µl. 24µl of FuGene 
HD were added to plasmids mix and incubated 20 minutes at room temperature. The transfection 
mix was transfered to the the packaging cells. The cells were incubated at 37 °C, 5% CO2. 18 
hours post-transfection the medium was replaced with fresh high-serum medium. After 24 hours 
the virus in the medium were harvested and the replaced with high-serum media. 24 hours after 
the first harvest, the virus were harvested and the packaging cells were discarded. The media 
containing virus were filtered with 0.45µm filter. The eluate was transferred to a sterile 
polypropylene storage tube. 
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RD cells were infected with 1ml (1 moi) of virus solution. After 18-24h of incubation the media 
were replaced with growth media. After 48h the media were replaced with growh media added 
with puromicine (final concentration 2µg/ml). 
4.4 Cell culture and differentiation
Myoblasts (C2C12) were grown in DMEM supplemented with 20% FBS 1% L-glutamine and 
antibiotics (Growth Medium, GM). Rhabdomyosarcoma cells RD were grown in DMEM 
supplemented with 10% FBS and antibiotics. The differentiation was induced by serum 
withdrawal in the presence of 2% horse serum (Differentiation Medium, DM). All cell lines were 
obtained from ATCC. Pellets were collected every 24h for 144h or 96h.
4.5 Immunoblotting
Cell were lysated in lysis buffer (20 mM Tris HCl pH 8; 137 mM  NaCl; 10% glycerol 1% 
Nonidet P-40; 2 mM EDTA; Protease Inhibitor Cocktails)
The protein concentration was determined by Bradford assay (Biorad, CA), following the 
manufacturer’s instructions and by using BSA as a standard.
The protein extract (50µg) was resolved in 8% SDS/PAA gel and transferred to a nitrocellulose 
membrane at 4°C and at 100V for 1h.The blots were blocked with TBS-T containing 5% non-fat 
dry milk.
The protein levels were detected with the followed antibody anti-Cdk9 (Rockland), Anti-
CyclinT2, anti-MyoD anti-Myogenin, anti-MYH (SANTA CRUZ) anti EZH2 (Invitrogen). Equal 
loading was controlled with anti-Gapdh and anti-Hsp70 (SANTA CRUZ). 
Antibody were used in TBS-T containing 3% non-fat dry milk. Anti-mouse, rabbit (1:10000), 
goat (1:2500) peroxidase conjugated (Pierce) and ECL detection system (PerkinElmer) were 
used for detection. 
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4.6 Total RNA extraction, cDNA synthesis and Real Time PCR
Total RNA was extracted from 5–10 x 106 cells using High Pure RNA Isolation Kit (Roche). 1µg 
of RNA was used for cDNA production with random primers, using High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems), following the manufacture’s protocol. 20µl of 
reaction was diluited in 200µl of sterile water.
Real Time was performed using 4,5µl of cDNA and 250 nM primers diluited in FastStart 
Universal SYBR Green Master (ROX), (Roche), to a final volume of 10µl. Amplification 
conditions for all amplicons were 95°C for 10 minutes, followed by 40 cycles of 95°C for 15s, 
60°C for 30s, 72°C for 30s.
Accumulation of fluorescent products was monitored using an Applied Biosystem 7300 system. 
Each data point was obtained from at least three independent experiments. Transcripts for 
glyceraldehyde-3-phosphate dehydrogenase were used as a reference. To ensure specific PCR 
amplification, every real time PCR run was followed by a dissociation phase analysis 
(denaturation curve) and by gel electrophoresis. ΔΔCT method was used to calculate relative 
changes in gene expression; primer efficiency was calculated for every target  using five x 10-








hGAPDH  GAAGGTGAAGGTCGGAGT  CATGGGTGGAATCATATTGGA
hCycT2a CAGGACTCCTCAGAACAGTGG TGTCCGTAGCCCACCTGAACT
hCycT2b CAACCACCACTCCAAAATGAGC GAGGAGGGGGTAAGGGATGG
hMyoD GACGGCATGATGGACTACAGC GGAGATGCGCTCCACGATGC  
hMyogenin CCTGCTCAGCTCCCTCAACC AGGGTCAGCCGTGAGCAGATG
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4.7 Transient transfections and luciferase assay
Transient transfections were performed using FuGene HD (Roche applied). 2µg of total DNA 
diluted in 100µl Opti-MEM (CellGro) was incubated with 8µl of FUGeneHD for 20 minutes to 
let the transfection complex form. The transfection complex was added in a ratio 1:16 to the 
volume of the incubation medium of the cells (6µl of transfection complex was added to 100µl of 
complete medium in 96 wells plate).
Dual luciferase reporter assay (Promega) was used to measure the firefly luciferase and renilla 
luciferase activity  within the transfected cells. Each experiment was conducted as suggested by 
the manifacturer. Luciferase assay was conducted on C2C12 myoblast transfected with the 
Myogenin-luc reporter, Myh-luc reporter, RL-TK renilla and expression vectors for CycT2a, 
CycT2b, Cdk9 and MyoD. The transfected cells were cultured in DM for 24h and 48h. 
Luciferase activity  was normalized to TK-directed Renilla expression, in a ratio 1:20 respect to 
firefly luciferase vector, to control for variability in transfection efficiencies. The assay  were 
performed with Sirius Luminometer (Berthold detection systems). 
The results are expressed in arbitrary  units relative to the activity of the basic luciferase vector 
(pGL3-myogenin/Myh promoter).
4.8 Nuclear extraction and Co-immunoprecipitation
For nuclei isolation cells were lysated with NP40 buffer (10mM  Tris-HCl; 10mM NaCl; 3mM 
MgCl2; 30mM Sucrose; 0.5% NP40; Protease Inhibitor Cocktails) for 30 minutes and 
centrifuged for 10 minutes at 3000 g. The pellet with the nuclei was washed with NP40 buffer 
and resuspended in non denturing lysis buffer (20 mM Tris HCl pH 8; 137 mM  NaCl; 10% 
glycerol 1% Nonidet P-40; 2 mM  EDTA; Protease Inhibitor Cocktails). Lysates were then 
sonicated at amplitude 30% in twice cycles of 30 sec, spaced out 15 sec, using a Fisher Model 
550 Sonic Dismembrator (Fisher, Pittsburgh, PA).
2mg of nuclear extract was precipitated with 2µg of anti-Cdk9 antibody (Rockland) or normal 
rabbit IgG. The immunoprecipitates were purified by  the addition of protein A-agarose (Roche) 
following the manufacturer’s instructions. Immunoblot were performed with anti-EZH2 
(Invitrogen).
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4.9 Espression and Purification of GST-fusion proteins, Translation and Binding in vitro
GST-Cdk9 and GST were generated by growing 400ml of recombinant E. coli BL21 culture at 
37°C to an A600 of 0.4. Cultures were induced for 4 hours with 1 mM IPTG. After induction, 
cultures were pelleted, resuspended in NETN buffer (20 mM  Tris HCl Ph 8; 100 mM NaCl; 1 
mM EDTA; 0.5% NP-40) containing 1mM PMSF and 1mM  DTT and sonicated at amplitude 
30% in six cycles of 1 minute, spaced out 30 seconds, using a Fisher Model 550 Sonic 
Dismembrator (Fisher, Pittsburgh, PA). The bacterial lysates were cleared of cellular debris by 
centrifugation and incubated with gluthatione agarose beads over night at 4°C. The complexes 
beads-GST and beads GST-Cdk9 were washed twice in NETN buffer 0.2M  once with RIPA 
buffer (50 mM Tris HCl pH 8; 150 mM NaCl; 1% NP-40; 0.5% Sodium deoxycholate) and once 
with NETN buffer 1mM PMSF and 1mM DTT. The complexes were resuspended in 150 µl of 
NETN buffer.
The TNT coupled reticulocyte kit was used for in vitro translation (Promega, WI, USA), 
according the manufacturer's instructions. All the samples were labeled using 35S- Methionine
10 µl of labeled samples were incubated with 10 µg of GST-CDK9 or GST as a negative control, 
in 150 µl of Buffer A (20 mM Tris HCl pH 8; 150 mM  KCl; 5 mM MgCl2; 0.2 mM EDTA; 10% 
Glycerol; 0.1% NP-40) containing DTT 1mM and PMSF 1mM. The samples then were washed 
in buffer A ,c and were resolved on 8% SDS-PAGE. The gels then were fixed with a fixing 
solution (50% methanol 10% glacial acetic acid) in slowly agitation for 30 minutes. Finally the 
gels were dried for 30 minutes at 80°C and subjected to autoradiography.
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5. RESULTS
5.1 Isolation and characterization of the murine Cyclin T2 cDNA
Murine cDNA of Cyclin T2 isoforms were cloned into pGEM-T Easy Vector System II and 
sequenced. The murine CycT2a and CycT2b, show 86% and 87% of similarity respect the 
human counteparts. Instead, the comparison between the amino acidic sequences show 85% and 
86% of similarity (Figure 7). The predicted molecular weights of CycT2a and CycT2b are 73 
kDa and 80 kDa respectively.
Figure 7: Cloning and sequencing of murine Cyclin T2 cDNA. (A) Similarity between human 
and murine isoforms. (B) Amino acid sequence of the murine Cyclin T2. The difference between 
the mouse and human protein sequence is denoted by a bar between the two.
A
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                                !   !         !                 
  MASGRGASSRWFFTREQLENTPSRRCGVEADEELSHRQQAANLIQDMGQRLNVSQLTINTAIVY
  MHRFYMHHSFTKFNKNIISSTALFLAAKVEEQARKLEHVIKVAHACLHPLEPLLDTKCDAYLQQ
                 !    !                                           
  MHRFYMHHSFTKFNRNIISPTALFLAAKVEEQARKLEHVIKVAHACLHPLEPLLDTKCDAYLQQ
  TQELVILETIMLQTLGFEITIEHPHTDVVKCTQLVRASKDLAQTSYFMATNSLHLTTFCLQYKP
       !                                                      
  TQELVLLETIMLQTLGFEITIEHPHTDVVKCTQLVRASKDLAQTSYFMATNSLHLTTFCLQYKP
  TVIACVCIHLACKWSNWEIPVSTDGKHWWEYVDPTVTLELLDELTHEFLQILEKTPNRLKKIRN
                                                          !   !
  TVIACVCIHLACKWSNWEIPVSTDGKHWWEYVDPTVTLELLDELTHEFLQILEKTPSRLKRIRN
  WRANQAARKPKVDGQVSETPLLGSSLVQNSILVDSVTGVPTNPSFQKPSTSAFPAPVPLNSGNI
     !!! !                                !          !    !     !!
  WRA--MAKKPKVDGQVSETPLLGSSLVQNSILVDSVTGVPANPSFQKPSTSTFPAPIPLNSGST
  SVQDSHTSDNLSMLATGMPSTSYGLSSHQEWPQHQDSARTEQLYSQKQETSLSGSQYNINFQQG
           !!     !  !       !          !     !!! !    !!      ! !
  SVQDSRASDNLSVLAAGMPSTSYSLSSHQEWPQHPDSARTDPVYTQKQEATLSGSQY-ISFQQG
  PSISLHSGLHHRPDKISDHSSVKQEYTHKAGSSKHHGPISTTPGIIPQKMSLDKYREKRKLETL
    !!           !     !                 !!   !!                  
  PSMALHSGLHHRPDKVADHSSAKQEYTHKAGSSKHHGPIPATPGMLPQKMSLDKYREKRKLETL
  DLDVRDHYIAAQVEQQHKQGQSQAASSSSVTSPIKMKIPIANT---EKYMADKKEKSGSLKLRI
   ! !    !  !!     ! !!  !!!!         ! !! !!!!  !! !   !
  DVDTRDHYLAAHAEQQHKHGPAQAVTGTSVTSPIKMKLPLTNSDRPEKHVAEKKERSGSLKLRI
  PIPPTDKSASKEELKMKIKVSSSERHSSSDEGSGKSKHSSPHISRDHKEKHKEHPSSRHHTSSH
      !  !!           !                                  !!   !
  PIPPPDKGPSKEELKMKIKVASSERHSSSDEGSGKSKHSSPHISRDHKEKHKEHPANRHH-SSH
  KHSHSHSGSSSGGSKHSADGIPPTVLRSPVGLSSDGISSSSSSSRKRLHVNDASHNHHSKMSKS
   !!!!!!!!!      !   !           !!! !  !  !!  !  !!!
  K----YLHMHSGGSKHTADGMPPTVLRSPVGLGPEGVSSASS-ARKKLHSSEASHNHHSKMSKS
  SKSSGGLRTSQHPRETGQEASGDQRSStop
     !               !  !!
  SKSAGGLRTSQHPRETGQETSGAPRSStop
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                               !   !         !                 
  MASGRGASSRWFFTREQLENTPSRRCGVEADEELSHRQQAANLIQDMGQRLNVSQLTINTAIVY
  MHRFYMHHSFTKFNKNIISSTALFLAAKVEEQARKLEHVIKVAHACLHPLEPLLDTKCDAYLQQ
               !    !                                           
  MHRFYMHHSFTKFNRNIISPTALFLAAKVEEQARKLEHVIKVAHACLHPLEPLLDTKCDAYLQQ
  TQELVILETIMLQTLGFEITIEHPHTDVVKCTQLVRASKDLAQTSYFMATNSLHLTTFCLQYKP
     !                                                      
  TQELVLLETIMLQTLGFEITIEHPHTDVVKCTQLVRASKDLAQTSYFMATNSLHLTTFCLQYKP
  TVIACVCIHLACKWSNWEIPVSTDGKHWWEYVDPTVTLELLDELTHEFLQILEKTPNRLKKIRN
                                                         !   !
  TVIACVCIHLACKWSNWEIPVSTDGKHWWEYVDPTVTLELLDELTHEFLQILEKTPSRLKRIRN
  WRANQAARKPKVDGQVSETPLLGSSLVQNSILVDSVTGVPTNPSFQKPSTSAFPAPVPLNSGNI
   !!! !                                !          !    !     !!
  WRA--MAKKPKVDGQVSETPLLGSSLVQNSILVDSVTGVPANPSFQKPSTSTFPAPIPLNSGST
  SVQDSHTSDNLSMLATGMPSTSYGLSSHQEWPQHQDSARTEQLYSQKQETSLSGSQYNINFQQG
          !!     !  !       !          !     !!! !    !!      ! !
  SVQDSRASDNLSVLAAGMPSTSYSLSSHQEWPQHPDSARTDPVYTQKQEATLSGSQY-ISFQQG
  PSISLHSGLHHRPDKISDHSSVKQEYTHKAGSSKHHGPISTTPGIIPQKMSLDKYREKRKLETL
  !!           !     !                 !!   !!                  
  PSMALHSGLHHRPDKVADHSSAKQEYTHKAGSSKHHGPIPATPGMLPQKMSLDKYREKRKLETL
  DLDVRDHYIAAQVEQQHKQGQSQAASSSSVTSPIKMKIPIANT---EKYMADKKEKSGSLKLRI
 ! !    !  !!     ! !!  !!!!         ! !! !!!!  !! !   !
  DVDTRDHYLAAHAEQQHKHGPAQAVTGTSVTSPIKMKLPLTNSDRPEKHVAEKKERSGSLKLRI
  PIPPTDKSASKEELKMKIKVSSSERHSSSDEGSGKSKHSSPHISRDHKEKHKEHPSSRHHTSSH
    !  !!           !                                  !!   !
  PIPPPDKGPSKEELKMKIKVASSERHSSSDEGSGKSKHSSPHISRDHKEKHKEHPANRHH-SSH
  KHSHSHSGSSSGGSKHSADGIPPTVLRSPVGLSSDGISSSSSSSRKRLHVNDASHNHHSKMSKS
 !!!!!!!!!      !   !           !!! !  !  !!  !  !!!
  K----YLHMHSGGSKHTADGMPPTVLRSPVGLGPEGVSSASS-ARKKLHSSEASHNHHSKMSKS
SKSSGSSSSSSSSVKQYISSHNSVFNHPLPPPPPVTYQVGYGHLSTLVKLDKKPVETNGPDANH  
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5.2 During the myogenesis, mRNA and protein levels of CycT2b are significantly higher 
respect to CycT2a levels
The muscle differentiation process was induced in murine myoblasts (C2C12) through serum-
deprivation triggering in presence of horse serum, for 144 hours (Figure 8). The CycT2a and 
CycT2b transcripts and proteins levels were analysed by Real-Time PCR and immunoblotting at 
several stages of differentiation (every 24 hours).
Immunoblot show that protein levels of CycT2b, in comparison to CycT2a are markedly  higher 
in all the stages of differentiation. The levels of Cyclin T2 increase during the myogenic 
program, (figure 9B). This results were confirmed by Real-Time PCR analysis that show that the 
levels of CycT2b cDNA are more or less 3.5 times higher respect the CycT2a cDNA levels 
(Figure 9A).
The myogenesis was verified by the evaluation of cells phenotype (figure 8) and the 
detemination of mRNA and protein espression of MyoD, Myogenin and MYH (Figure 9).
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Figure 8: C2C12 differentiation time course. Myoblasts (C2C12) were grown to 90% 
confluence in complete medium (GM, 20% FBS) and induced to differentiate by  serum 
withdrawal in the presence of 2% horse serum (DM) for 144h. Pellets were collected every 24h.
Irene Marchesi, A novel role of Cyclin T2 complexes in skeletal muscle and Rhabdomyosarcoma 
cells, Scuola di Dottorato in Scienze Biomolecolari e Biotecnologiche - indirizzo Biochimica, 
Biochimica Clinica e Biologia Molecolare, Universita’ degli Studi di Sassari
B
Figure 9: Espression of Cyclin T2 in C2C12 during the muscle differentiation. (A) Real-time 
quantitative PCR (qPCR) was used to determine relative mRNA expression levels upon 
induction of myogenesis. qPCR was performed using cDNA from myoblasts at  several stage of 
differentiation (24h-144h). To distinguish the two Cyclin T2 isoforms, specific primers were 
designed in the splicing site region. The myogenesis was verified by detemination of mRNA 
espression of MyoD, Myogenin and MYH. The reported data were normalized to 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels. (B) Immunoblot analysis The 
protein levels were detected with the followed antybody  Anti-Cyclin T2, anti-Cdk9, anti-MyoD 
anti-Myogenin, anti-MYH. Equal loading was controlled with anti-Gapdh and anti-Hsp70.
5.3 Cyclins T2 activate the muscle specific genes promoters; CycT2b have a predominat 
role in the latest stages of the myogenesis
To establish a functional difference between CycT2a and CycT2b, C2C12 myoblast were 
transiently  transfected with Myogenin promoter luciferase reporter (Myogenin-luc) and Myh 
promoter luciferase reporter (Myh-luc), and expression vectors for CycT2a, CycT2b, Cdk9, 
MyoD. The myoblasts were cultured in DM for 24h and 48h. 
Transfection of either individual or pairwise combinations of Cdk9, CycT2a and CycT2b 
expression vectors had no effect on Myogenin-luc and Myh-luc in the absence of MyoD. 
Conversely, MyoD-dependent transactivation of promoters was increased, by coexpression of 
both complexes Cdk9/CyclinT2 (Figure 10). At 24h, CycT2a and CycT2b had the same effect  on 
the myogenin-luc (Figure 10A); at 48h the effect of CycT2b in comparison to the effect of 
CycT2a was stronger (Figure 10C). On the Myh-luc the effect of CycT2b was stronger at both 
24h and 48h (Figure10 B,D). This suggest a predominant role of Cyct2b in latest stages of 
differentiation process.
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Figure 10: Regulation of Myogenin promoters by Cyclin T2. Luciferase assay was conducted 
on C2C12 myoblast transfected with the Myogenin-luc (A, C), Myh-Luc (B, D), RL-TK renilla 
and expression vectors for CycT2a, CycT2b, Cdk9 and MyoD. The transfected cells were 
cultured in DM  for 24h and 48h. Luciferase activity  was normalized to TK-directed Renilla 
expression. The results are expressed in arbitrary units relative to the activity of the basic 




5.4 RD cells show mRNA and protein levels of muscle specific genes lower and EZH2 levels 
significantly higher respect to C2C12 
To better understand the skeletal muscle differentiation process and the rhabdomyosarcoma 
formation, RD cells were grow 90% confluence in complete medium and induced to differentiate 
by serum withdrawal in the presence of 2% horse serum (DM) for 96h. Pellet were collected 
every 24h. 
After 96h unlike C2C12, RD cells failed to complete the differentiation program and they 
continued to proliferate (Figure 11A). Immunoblot showed that protein levels of all markers of 
myogenesis (MyoD, Myogenin and Myh) are markedly lower respect C2C12 differentiation 
program. Interestingly, the levels of EZH2, a protein frequently  overexpressed in several tumors, 
were considerably higher (Figure 11B). 
Figure11: C2C12 and RD differentiation time course. (A) Comparison between  C2C12 and 
RD phenotype after 96h in DM. (B) Immunoblot analysis. The protein levels were detected 
with the followed antybody anti-Cyclin T2, anti-Cdk9, anti-EZH2 anti-MyoD anti-Myogenin, 
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5.5 EZH2 inhibit the promoters of  several muscle specific gene
In order to understand the role of PCR2 in the rhabdomyosarcoma formation process a stable 
EZH2 knockdown RD cell line was generated using a vector-based shRNA. EZH2 knockdown 
cells did not show changes in cellular morphology.
The cells were induced to differentiate by serum withdrawal in the presence of 2% horse serum 
for 96h. Pellet were collected every 24h. 
Interestingly, analysis of mRNA and protein expression showed that EZH2 knockdown resulted 
in a significant increase on the MyoD, Myogenin and MYH levels (Figure 12). The partial 
reactivation of muscle specific genes, suggests a role of EZH2 in the inhibition of muscle 
differentiation program. 
Figure 12: Comparison between mRNA and protein espression in RD and RD EZH2 
knockdown . (A) Real-time quantitative PCR with specific primers for MyoD and Myogenin. 
(B) Immunoblot analysis. The protein levels were detected with the followed antybody: anti-
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5.6 EZH2 binds to Cdk9 and Cyclins T2 both in vitro and in vivo
To investigate whether EZH2 was able to interact with Cdk9 and with in vitro, Gst pull-down 
experiments were performed using Gst-Cdk9 and GST-EZH2 purified from BL21 E. Coli cells 
and four in vitro translated product [35S]-EZH2 full-length, [35S]-Cdk9, [35S]-CycT2a and [35S]-
CycT2b. As shown in figure 13A, Gst-Cdk9 was able to pull down full-length EZH2, while this 
was not the case for the Gst fragment alone. In addition, Gst-EZH2 was able to pull down both 
Cyclin T2 isoforms, showing a direct interaction between EZH2 and Cyclins T2 (Figure 13B,C).
Moreover in order to test if EZH2 and Cdk9 were able to interact in Rhabdomyosarcoma cells, 
RD cells lysates were subjected to Co-immunoprecipitation with anti-Cdk9 and 
immunoprecipitation were then probed with anti-EZH2 (Figure 14). Normal Rabbit IgGs have 
been used as negative control.
Figure 13: Binding in vitro assay: EZH2 binds to  Cdk9, CycT2a and CycT2b in vitro. (A)
Physical interaction between Gst-Cdk9 and in vitro translated EZH2. (B) Physical interaction 
between Gst-EZH2 and in vitro translated CycT2a and CycT2b.
B
A
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Figure 14: Co-immunoprecipitation. RD cells lysates were co-immunoprecipitated with anti-
Cdk9 and Normal Rabbit  IgG as negative control. Immunoblotting was performed with anti-
EZH2.  
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6. DISCUSSION
During cell division, cyclins play  an essential role being subjected to cyclical expression and 
ubiquitin-dependent degradation, and acting as regulatory subunits of complexes with the cyclin-
dependent kinases (CDKs) (Sherr, 1996; Grana and Reddy, 1995). 
Some CDKs/cyclin, as CDK7/cyclin H, CDK8/ cyclin C, and CDK9/cyclin T, seem to direct 
their activity in a cell cycle independent manner and appear to be involved in other processes as 
signal transduction, apoptosis, differentiation and transcription during the initiation or the 
elongation steps (Dynlacht, 1997; De Luca et al., 2003).
A Previous study showed that Cdk9, in association with Cyclin T2, plays an important role in the 
activation of the myogenic program (Simone et al., 2002b). Upon induction of muscle 
differentiation, MyoD recruits Cdk9/CycT2 on muscle-specific gene promoter sequences. This 
complex is able to phosphorylate the C-terminal domain (CTD) of RNA polymerase II, 
enhancing MyoD function and promoting myogenic differentiation (Giacinti et al., 2006). The 
transcriptional activity  of MyoD is deficient in rhabdomyosarcoma cells and in these cells, Cdk9 
fails to phosphorylate MyoD (Simone and Giordano, 2007). 
EZH2 is the catalytic subunit of PRC2 and is responsible of the lysine-27 tri-methylation of 
histone H3. 
Gene expression silencing by PcG proteins, is required at specific stages of development and is 
down-regulated in adult differentiated tissues (Varambally  et al., 2002; Bracken et al., 2003; 
Kleer et al., 2003). PcG is able to regulate embryonic development of muscle inhibiting the 
homeobox gene expression (Caretti et al., 2004). Interestingly, EZH2 is overexpressed in a 
variety of different tumors as in the rhabdomyosarcoma. 
This work focuses on the evaluation of role of Cdk9/Cyclin T2 complexes during the skeletal 
muscle differentiation and in rhadbomyosarcoma cells.
In order to understand the role of Cyclin T2 isoforms in muscle differentiation, myogenesis was 
induced in murine myoblast and mRNA and protein levels were analyzed at several stage of 
differentiation process. In addition, luciferase assay  performed allowed to identify functional 
differences  between two complexes.
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The results demonstrated that CycT2b levels, both mRNA and protein expressions, in 
comparison to CycT2a are markedly higher in all the stages of differentiation. These results 
assumed a major role for CycT2b in muscle differentiation process. Moreover the luciferase 
assay showed that both cyclins T2 isoforms was able to increased MyoD-dependent 
transactivation of Myogenin and Myh promoters. During the first stages of differentiation both 
Cyclins T2 activate the muscle differentiation program but during the latest stages the activity  of 
CycT2b is stronger.
The higher espression and the differences of functional activity show by CycT2b suggest a 
predominant role of this protein in the differentiation process, in particular during the latest 
stages.
Rhabdomyosarcoma (RMS) is one of the most common childhood solid tumor that arises from 
muscle precursor cells. In RMS cells, the ability  of MyoD to arrest cell proliferation and to 
activate the myogenic program is repressed and the myoblasts fail to complete the differentiation 
program (Tapscott et al. 1993; Otten et al. 1997; Merlino and Helman, 1999). Moreover, Cdk9 
fails to phosphorylate MyoD but no mutations were detected in the coding sequences of Cdk9 
and Cyclin T2 (Simone and Giordano 2007). This allow to hypothesize that the MyoD inhibition 
arise from inhibition of Cdk9 activity.
The comparison between normal myoblast (C2C12) and RMS cells (RD) proteins levels 
confirmes that the expression of muscle specific genes is inhibited in RD cells whereas Cdk9 is 
strongly expressed. Interestingly, EZH2 a protein involved in the regulation of differentiation 
process of several tissue as in skeletal muscle differentiation, is overexpressed. EZH2 is the 
catalytic subunit of Polycomb repressive complex 2 (PRC2), which is histone methyltransferase 
that targets lysine-27 of histone H3 responsible of silencing ot target genes. Typically, EZH2 is 
down-regulated in adult differentiated tissues but over-expressed in a wide variety of cancerous 
tissue types (for review Simon and Lange 2008). Previous study showed that PRC2 plays a key 
role in the maintenance of the undifferentiated state of muscle cell precursors (Caretti et al., 
2004 ).
In order to understand if the overexpression of EZH2 was the cause of rabdomyosarcoma 
formation, a stable EZH2 knockdown RD cell line was generated and induced to differentiate. 
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Interestingly, EZH2 knockdown allow a significant increase on the MyoD, Myogenin and MYH 
levels. The partial reactivation of muscle specific genes confirm the hypothesis that EZH2 
overexpression contribuite to inhibition of muscle differentiation program.
To investigate whether the inhibition of Cdk9 in Rabdomyosarcoma cells and overexpression of 
EZH2 was interrelated, we assumed an interaction between Cdk9 and EZH2. We confirmed the 
interaction between the two proteins by alternative methods, co-immunoprecipitation and in vitro 
pull-down assays. Moreover we demonstrate that EZH2 is able to interact with both CycT2a and 
CycT2b.
These studies highlight a critical role for Cdk9/CycT2b complex in controlling skeletal muscle 
growth and differentiation. Our observation point toward the cooperation with MRFs such as 
MyoD and Myogenin suggesting that CycT2b has a crucial role in maintaining cells at the 
differentiation terminal stage. In addition, the physical interaction between Cdk9/Cyclin T2 
complex and EZH2 emphasizes its commitment to the skeletal muscle lineage. It is reasonable to 
assume that during myogenesis Cdk9/Cyclin T2 complex might be implicated in the 
downregulation of EZH2, a step that is functionally required for the process of myotube 
formation.
The understanding of the functional properties of the Cdk9/Cyclin T2 complexes and the 
interaction with specific associated partners will help  us to clarify  the complex mechanisms that 
regulate the myogenic program. Moreover, the characterization of the binding between Cdk9 and 
myogenic regulatory factors like EZH2 may contribuite to explain the most important pathways 
involved in muscle program regulation and rhabdomyosarcoma formation.
 Further studies are on going in our laboratory to define more accurately the molecular 
mechanisms underlying the myogenic function of Cdk9/CyclinT2 complexes with EZH2, and to 
verify its biological relevance in rhabomyosarcoma formation.
.
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